<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61658">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303236</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2012-092-B</org_study_id>
    <nct_id>NCT02303236</nct_id>
  </id_info>
  <brief_title>Biological Markers Predicting Exercise Capacity in CF-LVAD Patients.</brief_title>
  <official_title>Biological Markers Predicting Exercise Capacity in Heart Failure Patients Supported With a Continuous-flow Left Ventricular Assist Device.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Establishing the association between biological markers and exercise capacity in
      continuous-flow left ventricular assist device patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to investigate if specific biological markers can predict exercise
      capacity in advanced heart failure patients supported with continuous-flow left ventricular
      assist device patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biological markers</measure>
    <time_frame>Blood sampling on study day and samples are subsequently stored frozen.</time_frame>
    <description>Analysis of blood will be carried out on all samples simultaneously, expected markers are pro-BNP, MRproANP, copeptin, Gal-3 and proADM.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>Examination on study day. Patients will only be followed on the day of the study. Exercise testing is performed as the last intervention on the study day.</time_frame>
    <description>Exercise capacity will be estimated by peak VO2 measurements on a upright ergometer bike with breath-by-breath gas analysis.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Heart Failure.</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples in biological bank.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stable CF-LVAD patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable CF-LVAD patients.

        Exclusion Criteria:

          -  Unstable CF-LVAD patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Finn Gustafsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette Jung, MD</last_name>
    <phone>+45 23 48 47 34</phone>
    <email>metteholmejung@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Finn Gustafsson, MD, Ph.D</last_name>
    <phone>+ 35 45 97 43</phone>
    <email>finng@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Rigshospitalet.</name>
      <address>
        <city>Copenhagen</city>
        <state>Kbh Oe</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Jung, MD</last_name>
      <phone>+ 45 23 48 47 34</phone>
      <email>metteholmejung@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Finn Gustafsson, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 26, 2015</lastchanged_date>
  <firstreceived_date>November 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Finn Gustafsson</investigator_full_name>
    <investigator_title>MD, Ph.D</investigator_title>
  </responsible_party>
  <keyword>Exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
